Industry Detail

The 9MM Tenosynovial Giant Cell Tumour Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR 12.31% over the projected period. And by 2033, the market is expected to touch USD XX Million.

Tenosynovial Giant Cell Tumour Market Outline:

Tenosynovial giant cell tumour (TGCT), also known as giant cell tumour of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), is a rare, non-cancerous (benign) tumour that affects the synovium, which is the lining of the joints, tendon sheaths, and bursae. 

TGCT commonly occurs in the joints of the hands and fingers, but it can also affect larger joints such as the knee, hip, and ankle. The tumour can cause pain, swelling, and stiffness in the affected joint. In some cases, it may lead to limited range of motion. The symptoms can vary depending on the location and size of the tumour.

Tenosynovial Giant Cell Tumour Disease Burden Analysis:

• TGCT is considered an orphan disease, with reported incidence rates ranging from 30–39 and 5–8 per million person-years for L-TGCT and D-TGCT, respectively 
• A number of treatment and management algorithms have been described and these are frequently sub-classified into drug treatment, radiation therapy and surgical intervention
• United States accounting for largest patient pool

Treatment Landscape:

Treatment options for TGCT include surgery and, in some cases, medical therapies. Surgical options may involve removing the tumour or, in more extensive cases, synovectomy (removal of the synovial lining). Medical therapies may include medications to help control the symptoms and reduce the risk of recurrence. TGCT has a tendency to recur even after treatment. Recurrence rates vary, and long-term follow-up is often required.

Report Insights:

• More than 25 clinical trials, United States is the dominated region
• Huge unmet need exists
• Localized tenosynovial giant cell tumours are most prevalent in the fingers (~85%) 
• Tenosynovial giant cell tumours mainly affect individuals between 25-50 years of age, with a median age of diagnosis of 40
• Report has investigated the potential molecular target such as CSF1- CSF1R axis, JAK2, cIAP2, B-Arrestin2, PPARγ, TNF-α and others along with investigational drugs.
• Opportunity worth of USD 2,443.7 million is expected to roll out in the market
• CSP Analytics Solutions provided the clinical mapping of key pipeline molecules
• CSP Analytics Solutions also analysed the unmet need and patients treatment gaps in the market. 
• Tenosynovial Giant Cell Tumour market is struggling to get effective treatment

Market Segmentation Analysis by:

• By Line of Therapy:
  • First-line of therapy
  • Second-line of therapy
• By Disease Type:
  • Localized Giant Cell Tumour
  • Diffuse Giant Cell Tumour
• By Treatment Type:
  • Drug Therapy
  • Radiation Therapy
• By Route of Administration:
  • Oral
  • Intravenous
  • Intra-articular

Market Enablers: Explored in report

• Untreated Prevalent Pool of Tenosynovial Giant Cell Tumour Drug
• Growing Clinical Trial Activities 
• Huge Market Unmet Need
• Rising drug Penetration in Tenosynovial Giant Cell Tumour Segment

Market Challenges: Explored in report

• Lack of Efficacious Treatment Options
• Cost of Treatment
• Inadequate Reimbursement 
• Underdiagnoses in Emerging Market

Regional Outlook: 

Report has fragmented the total market in five regions such as US, 5-Europe, China, Japan, India and RoW (Rest of world). 

Each mapped region has been examined at granular level based on certain parameters:

• United States Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• 5-Europe Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• China Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• India Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• Japan Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• Rest of the World Tenosynovial Giant Cell Tumor Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)

Competitive Landscape: 

Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Companies Profile:

• Novartis
• Roche
• Daichii-Sankyo
• Five Prime therapeutics
• Dicephera Pharmaceuticals LLC
• Nippon Chemiphar
• Abbisko Therapeutics Co, Ltd
• AmMax Bio, Inc.
• Plexxikon
• SynOx Therapeutics Limited
• Others

Pipeline molecules investigated in the report:

Unlock Disease Forecast Model: